Cardiovascular Diseases

ATTR Cardiomyopathy Drug Approved

The US FDA approved tafamidis meglumine (Vyndaqel) and tafamidis (Vyndamax) for the treatment of wild-type or hereditary transthyretin amyloid (ATTR) cardiomyopathy based on a trial that showed a significant reduction in mortality, cardiovascular hospitalizations, and in decline in functional capacity and quality of life. The multicenter, international, double-blind, placebo-controlled, phase 3 trial, randomly assigned 441 patients with ATTR cardiomyopathy in a 2:1:2 ratio to receive 80 mg of tafamidis, 20 mg of tafamidis, or placebo for 30 months. Tafamidis was associated with lower all-cause mortality than placebo (29.5% vs. 42.9%; hazard ratio, 0.70) and a lower rate of cardiovascular-related hospitalizations, with a relative risk ratio of 0.68 (0.48 vs. 0.70 per year). At month 30, tafamidis was also associated with a lower rate of decline in distance for the 6-minute walk test and in quality of life score. The incidence and types of adverse events were similar in the tafamidis and placebo groups. The findings indicate that tafamidis is an effective therapy for patients with ATTR cardiomyopathy. ATTR cardiomyopathy is a life-threatening disease characterized by the accumulation of amyloid fibrils composed of misfolded transthyretin protein in the heart with symptoms  predominately manifested in male patients 60 years of age or older. Source: https://www.fda.gov/; https://www.nejm.org/

hyangiu

Recent Posts

Mediterranean Diet May Slow Atherosclerosis Progression and Prevent CHD

A Spanish secondary prevention study suggested that Mediterranean diet might reduce neutrophil levels and slow…

5 days ago

2024 Strategies and Criteria for the Diagnosis and Management of Myocarditis

Top 10 key takeaway points of the report of the American College of Cardiology Solution…

2 weeks ago

Irregular Sleep Linked to Higher CVD Risk

A UK device-based prospective study suggested that irregular sleep was associated with higher risk of…

4 weeks ago

Intensive BP Control Benefits T2D Patients

A Chinese parallel design, randomized clinical trial showed that the incidence of major cardiovascular events…

1 month ago

Early-Life Sugar Restriction Protective on T2D and High Blood Pressure

A study comparing UK adults conceived just before or after sugar rationing ended found that…

1 month ago

Cold Weather Linked to Higher MI Risk

A Chinese nationwide case-crossover study revealed that lower temperatures were associated with higher risks of…

2 months ago

This website uses cookies.